BIOL stock icon

Biolase
BIOL

$0.15
2.82%
 

About: Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Employees: 157

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

20% more funds holding

Funds holding: 15 [Q4 2023] → 18 (+3) [Q1 2024]

6.84% less ownership

Funds ownership: 8.74% [Q4 2023] → 1.9% (-6.84%) [Q1 2024]

65% less capital invested

Capital invested by funds: $336K [Q4 2023] → $116K (-$219K) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$0.4
175%
upside
Avg. target
$1.6
1,002%
upside
High target
$4
2,655%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Benchmark
Bruce Jackson
175%upside
$0.4
Speculative Buy
Reiterated
14 May 2024
Ascendiant Capital
Edward Woo
2,655%upside
$4
Buy
Maintained
1 Apr 2024
Benchmark
Bruce Jackson
175%upside
$0.4
Speculative Buy
Maintained
22 Mar 2024

Financial journalist opinion

Neutral
Accesswire
1 month ago
Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability
Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success LAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024. First Quarter Financial Highlights Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialists Third strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptions Gross margin was relatively flat compared to the year-ago quarter; however, it improved by 1% year over year as the Company continues to benefit from 100% of its trunk fiber requirements now being supplied in-house and improved by 7% compared to the prior quarter from inventory adjustments and reserve charges recorded in the fourth quarter ended December 31, 2023 Significantly lowered Adjusted EBITDA loss by 21% versus the same quarter last year, as cost reduction initiatives achieved desired outcomes Full Year 2024 Financial Guidance Reiterates 2024 full-year financial guidance, in which it expects: 2024 full-year net revenue to increase between 6% and 8% year over year to between $52 million and $53 million.
Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability